Month: June 2023

DUBAI, the United Arab Emirates, June 30, 2023 (GLOBE NEWSWIRE) — OKX, the second-largest crypto exchange by trading volume and a leading Web3 technology company, has issued updates for the day of June 30, 2023.

OKX Liquid Marketplace Exceeds Over USD$3 Billion in Institutional Trading Volume, Records Milestone

OKX is proud to announce that its Liquid Marketplace, an on-demand liquidity network for institutional traders, exceeded USD$3 billion in trading volume. This milestone is a testament to the Liquid Marketplace’s success in providing institutional traders with deep liquidity and reliable execution.

This announcement follows the launch of the ‘Nitro Spreads’ feature on the OKX Liquid Marketplace, an OTC, futures spreads and options liquidity network, allowing traders to make complex basis trades with simple one-click execution.

Selected institutional clients who applied for early access via the Liquid Marketplace website can now use Nitro Spreads; wider access will be available to other institutional clients starting 5 July.

Nitro Spreads is one of the only basis trading tools in the crypto market in which the two legs of the trade are executed together via a central order book, eliminating leg risk between markets. Traders can select a guaranteed spread for a trade, eliminating the risk of the order for one leg being completed without the other. Trades are then matched and settled immediately.

The OKX Liquid Marketplace provides access to deep institutional liquidity and a number of crypto trading strategies, including futures spreads, large options block trades, or spot OTC, to run at scale. In April 2023, OKX announced that the Liquid Marketplace exceeded USD$1 billion in trading volume during the first three months of 2023, and as of the end of June 2023, the trading volume has more than tripled that figure.

To enhance its offering for institutional users, OKX is also expanding custody solutions by partnering with firms like Komainu to give institutional clients more transparency and control over funds while balancing capital efficiency, cost and security.

For more information, please visit the Support Center.

For further information, please contact:

Media@okx.com

About OKX

OKX is the second-largest global crypto exchange by trading volume and a leading Web3 ecosystem. Trusted by more than 50 million global users, OKX is known for being the fastest and most reliable crypto trading app for traders everywhere.

As a top partner of English Premier League champions Manchester City FC, McLaren Formula 1, Olympian Scotty James, and F1 driver Daniel Ricciardo, OKX aims to supercharge the fan experience with new engagement opportunities. OKX is also the top partner of the Tribeca Festival as part of an initiative to bring more creators into web3.

Beyond OKX’s exchange, the OKX Wallet is the platform’s latest offering for people looking to explore the world of NFTs and the metaverse while trading GameFi and DeFi tokens. We’re also building our institutional offering by expanding our trading capabilities and championing product innovation, such as our recent partnership with Komainu Connect.

OKX is committed to transparency and security and publishes its Proof of Reserves on a monthly basis.

To learn more about OKX, download our app or visit: okx.com

Disclaimer

THIS ANNOUNCEMENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY. IT IS NOT INTENDED TO PROVIDE ANY INVESTMENT, TAX, OR LEGAL ADVICE, NOR SHOULD IT BE CONSIDERED AN OFFER TO PURCHASE, SELL, OR HOLD DIGITAL ASSETS. DIGITAL ASSETS, INCLUDING STABLECOINS, INVOLVE A HIGH DEGREE OF RISK, CAN FLUCTUATE GREATLY, AND CAN EVEN BECOME WORTHLESS. OKX IS NOT REGULATED BY THE FCA, THUS, PROTECTIONS SUCH AS THE FINANCIAL OMBUDSMAN SERVICE OR FINANCIAL SERVICES COMPENSATION SCHEME WILL NOT BE AVAILABLE. YOU SHOULD CONSIDER WHETHER YOU UNDERSTAND HOW CRYPTO WORKS AND WHETHER TRADING OR HOLDING DIGITAL ASSETS IS SUITABLE FOR YOU IN LIGHT OF YOUR FINANCIAL CONDITION. THE VALUE OF YOUR DIGITAL ASSETS, INCLUDING STABLECOINS, CAN INCREASE OR DECREASE AND PROFITS MAY BE SUBJECT TO CAPITAL GAINS TAX. PAST PERFORMANCE DOES NOT INDICATE FUTURE RESULTS. PLEASE CONSULT YOUR LEGAL/TAX/INVESTMENT PROFESSIONAL FOR QUESTIONS ABOUT YOUR SPECIFIC CIRCUMSTANCES.

GlobeNewswire Distribution ID 8867388

• Highlights key initiatives that will drive the company’s transition towards a more sustainable business
• Reaffirms commitment to environmentally and socially responsible practices in R&D, clinical trials, manufacturing, and supply chain management to enable access to high-quality biological medicines for patients in need

INCHEON, Korea, June 30, 2023 (GLOBE NEWSWIRE) — Samsung Bioepis Co., Ltd. today released its 2023 sustainability report, highlighting its progress toward building more sustainable and socially responsible practices in research and development (R&D), clinical trials, manufacturing, and supply chain management.

“The consequences of the COVID-19 pandemic such as global supply chain disruptions, as well as the growing challenges of climate change have highlighted the importance of sustainable business, and this report embodies our commitment to reinforcing our environment, social, governance values and initiatives,” said Christopher Hansung Ko, President and Chief Executive Officer at Samsung Bioepis. “We will provide patients with wide-ranging portfolio of biologics products at affordable prices and promote win-win partnerships across the bio industry ecosystem.”

Together with Samsung Biologics, Samsung Bioepis is committed to joining the RE100 initiative, a group of global corporations pledging to shift to 100% renewable energy by 2050, and the company also targets to reach net-zero emissions by 2050.

The annual report provides a comprehensive overview of Samsung Bioepis’ performance and management of the company’s commitment to sustainability, and key highlights of the report are as follows:

Driving R&D Innovation
Samsung Bioepis pursues transformation and innovation throughout its business activities to drive its sustainable growth and to help address important issues that matter to our business, our stakeholders and society.
The company’s innovative research and development is the key to increase access to scientifically-proven medicines for patients around the world and unlock the potential of biosimilars.

Ensuring Product Quality and Patient Safety
Ensuring product quality and patient safety are at the center of Samsung Bioepis’ vision and priorities. Samsung Bioepis has rigorous quality management system in compliance with global standards to prevent quality risks.
Clinical trials are a critical part of patient safety, and Samsung Bioepis strives to adhere to strict global standards when it comes to pre-clinical and clinical trials.

Enhancing Access to Medicines
Samsung Bioepis holds on the mission of innovating access to medicines for patients worldwide. At the core of our business and vision are the patients around the world without viable treatment options, and the company is further committed to fulfilling its social responsibility and becoming a sustainable company.

Building Sustainable Supply Chain Management
Samsung Bioepis emphasizes the importance of ensuring that its products are delivered on time, so that patients can receive treatments at the right time. Sustainable supply chain management and supply continuity are the most important aspects of the company’s mission and promise to patients that we will deliver the high-quality medicines they need.
The company also takes the impact of our activities seriously throughout the entire supply chain by conducting ESG assessments of its existing supply chains on a regular basis and reviewing its suppliers’ human rights, code of ethics and environmental performance.

The company’s report is formulated in the Core Options of the Global Reporting Initiative (GRI) Standards and details activities and achievements that are aligned with the Sustainability Accounting Standards Board (SASB). Samsung Bioepis’ detailed ESG performance can be found in the full report: https://bit.ly/3NR2obo

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.

MEDIA CONTACT
Jane Chung, ejane.chung@samsung.com
Anna Nayun Kim, nayun86.kim@samsung.com

GlobeNewswire Distribution ID 8866746

SOUTHAMPTON, Pa., June 29, 2023 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded a $17.3 million contract from a multi-national medical device manufacturer. The contract includes four, thirty pallet ethylene oxide (“EO”) sterilization chambers and four, thirty pallet vacuum aeration (de-gassing) chambers. “This contract reflects ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially designed to meet unique process systems challenges.

About ETC
ETC designs, manufactures, and sells software-driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC’s headquarters is in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements
This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

Contact:		Robert L. Laurent, CEO & President
Phone:		(215) 355-9100
E-mail:		info@etcusa.com

GlobeNewswire Distribution ID 8867253

Basseterre, June 29, 2023 (GLOBE NEWSWIRE) — International investors have been clamouring to take advantage of one of the best deals in the investment migration industry this year – St Kitts and Nevis’ Sustainable Growth Fund (SGF) Limited Time Offer (LTO) which allows investors to gain approval for alternative citizenship in the country in as little as 60 days for a reduced fee.

In December 2022, the St Kitts and Nevis Head of the Citizenship by Investment Unit (CIU), Michael Martin, announced the enactment of the updated St Kitts and Nevis Citizenship by Investment Regulations 2023, which included the introduction of the LTO for the SGF investment option effective 1 January 2023 – 30 June 2023.

On 29 June 2023, Michael Martin made the following comment regarding the LTO:

“We have received an overwhelming response and demand for our Sustainable Growth Fund investment option through the Limited Time Offer and felt that we had to extend the offering for another seven months until 31 January 2024. International investors continue to see the value of the world’s first and finest Citizenship by Investment Programme and this proves it”.

The SGF remains the quickest and easiest route to alternative citizenship in St Kitts and Nevis and now until 31 January 2024, a main applicant can acquire alternative citizenship by contributing only US$125,000 to the SGF and receiving approval in principle within 60 days of acknowledgement by the CIU of submission of their application.

Under the LTO, the minimum SGF contributions are as follows:

• Single applicant – US$ 125,000
• Main applicant and a spouse – US$150,000

• Main applicant and up to three dependants – US$170,000
• Each additional dependant under 18 – US$10,000
• Each additional dependant over 18 – US$25,000

Revenue from the SGF has facilitated economic development and social upliftment in the country. The SGF is used to provide financial support to educational institutions, and medical facilities, as well as support infrastructural development, increase tourism, preserve local culture and heritage and support sustainable growth initiatives in the twin-island nation.

Discerning investors are seeing the benefits of being part of St Kitts and Nevis’ success story. Following upgrades to the CBI Regulations, the country now offers one of the most secure and best-regulated investment migration offerings in the world.

This means that international investors looking to hedge their bets in a stable and growing economy should look no further than St Kitts and Nevis.

This extension is a fantastic opportunity for investors to obtain citizenship through the LTO. This is a final extension and from 1 February 2024, the minimum SGF contribution will increase to the amounts prior to the LTO period.

The country is making sure that it has only the best to offer international entrepreneurs and families who have realised that global powerhouses are no longer illustrious investment options due to security risks. Investors want to ensure that they can safeguard their families and wealth in a global economy that has been offering nothing but uncertainty since the onset of the COVID-19 pandemic in 2020.

Smaller governments such as that of St Kitts and Nevis have found ways, through CBI, to protect themselves from global shocks, offer favourable business policies aimed at growing corporations in international markets and, by using international funds channelled to the SGF, can diversify and grow their economy to meet global needs.

St Kitts and Nevis continues to create a name for itself as a financial nexus in the Caribbean with an attractive CBI programme underpinned by a sound legal framework and robust multi-layered due diligence.

For nearly 40 years, St Kitts and Nevis has been the pioneer of the global investor immigration industry and those who recognise this are taking advantage of the LTO.

St Kitts and Nevis continues to create a name for itself as a financial nexus in the Caribbean with an attractive CBI programme underpinned by a sound legal framework and robust multi-layered due diligence.

For nearly 40 years, St Kitts and Nevis has been the pioneer of the global investor immigration industry and those who recognise this are taking advantage of the LTO.

Chantal Mabanga
Government of St. Kitts and Nevis
+44 (0) 207 318 4343
chantal.mabanga@csglobalpartners.com

GlobeNewswire Distribution ID 8867177